LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Recursion Pharmaceuticals Inc

Închisă

SectorSănătate

4.84 1.68

Rezumat

Modificarea prețului

24h

Curent

Minim

4.66

Maxim

4.9

Indicatori cheie

By Trading Economics

Venit

31M

-172M

Vânzări

4.4M

19M

Marjă de profit

-899.843

Angajați

800

EBITDA

44M

-148M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+24.74% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

-432M

2.1B

Deschiderea anterioară

3.16

Închiderea anterioară

4.84

Sentimentul știrilor

By Acuity

50%

50%

185 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 sept. 2025, 17:03 UTC

Principalele dinamici ale pieței

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sept. 2025, 16:49 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

GD Culture Shares Drop After Deal for Pallas Capital

16 sept. 2025, 16:11 UTC

Principalele dinamici ale pieței

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sept. 2025, 23:40 UTC

Market Talk

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sept. 2025, 23:34 UTC

Market Talk

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sept. 2025, 23:20 UTC

Market Talk

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sept. 2025, 21:10 UTC

Achiziții, Fuziuni, Preluări

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sept. 2025, 20:51 UTC

Market Talk

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

16 sept. 2025, 20:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Basic Materials Roundup: Market Talk

16 sept. 2025, 20:25 UTC

Câștiguri

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sept. 2025, 20:24 UTC

Câștiguri

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sept. 2025, 19:19 UTC

Market Talk

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sept. 2025, 18:52 UTC

Market Talk

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

Global Equities Roundup: Market Talk

16 sept. 2025, 18:44 UTC

Market Talk

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sept. 2025, 18:40 UTC

Achiziții, Fuziuni, Preluări

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sept. 2025, 18:38 UTC

Market Talk

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sept. 2025, 18:19 UTC

Market Talk

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sept. 2025, 18:01 UTC

Market Talk

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sept. 2025, 17:34 UTC

Market Talk

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sept. 2025, 16:53 UTC

Câștiguri

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sept. 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Basic Materials Roundup: Market Talk

16 sept. 2025, 16:15 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Commodities Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Energy Roundup: Market Talk

16 sept. 2025, 16:09 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 sept. 2025, 15:35 UTC

Market Talk

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sept. 2025, 15:22 UTC

Market Talk

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sept. 2025, 15:21 UTC

Market Talk

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparație

Modificare preț

Recursion Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

24.74% sus

Prognoză pe 12 luni

Medie 5.95 USD  24.74%

Maxim 8 USD

Minim 3 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRecursion Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

1

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

4.15 / 4.75Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

185 / 371 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat